A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors

Prior treatment

• Patients with concurrent multiple or synchronous cancers, or with iatrogenic multiple or synchronous cancers with a disease-free interval of 5 years or less.
• Patients receiving continuous systemic administration of steroids or other immunosuppressive drugs.
• Patients who have not recovered to Grade 1 or below from adverse events caused by previously administered anticancer therapy.

Other illness

• Patients who have had a Grade 3 or higher allergic reaction to an antibody agent or an additive of the study drug.
• Patients with active interstitial lung disease or a history of active interstitial lung disease.
• Patients with infectious diseases requiring systemic treatment.
• Patients who test positive for Hepatitis B virus antigen or antibody, Hepatitis C virus antibody, or HIV antibody in a baseline test.

Other

• \<Common Exclusion Criteria to Part 1 and Part 2\>
• Patients with central or brain pia mater metastases that are untreated and symptomatic or that require treatment.
• Patients with a fever of 38.0°C or higher at the time of registration.

• \<Common Inclusion Criteria for Part 1a, Part 1b, and Part 2
• Patients who have given informed written consent.
• Male or female subjects ≥18 years of age, at time of signing informed consent.
• Subjects who are refractory to standard treatment, intolerant of standard treatment, for whom standard treatment does not exist, or who have refused standard treatment.
• Patients with measurable disease according to RECIST version 1.1
• Patients who have had the certaion periods between the date of completion of prior therapy and the date of enrollment
• Subjects who agree to have a tumor biopsy as part of the baseline examination. Patients who have difficulty in performing a tumour biopsy and have agreed to submit a previously collected stored specimen.
• Patients with an ECOG PS of 0 or 1 at baseline.
• Patients with haematopoietic, hepatic, renal, cardiac and respiratory functions that meet certain criteria in a baseline test.
  • \<Additional Inclusion Criteria for Part 1a
  • 1\) Patients with pathologically diagnosed advanced or metastatic solid tumors.
  • \<Additional Inclusion Criteria for Part 1b
• Patients with pathologically diagnosed with advanced or metastatic esophageal cancer, or advanced or metastatic head and neck cancer whose primary site of origin is the oral cavity, oropharynx, hypopharynx, larynx, nasal cavity, or paranasal sinuses.
• Patients with pathologically diagnosed squamous cell carcinoma.
• Patients who agree to undergo tumor biopsy after administration.
  • \<Additional Inclusion Criteria for Part 2a
• Patients with pathologically diagnosed with advanced or metastatic esophageal cancer.
• Patients with pathologically diagnosed squamous cell carcinoma.
• Patients who agree to undergo tumor biopsy after administration.
  • \<Additional Inclusion Criteria for Part 2b
• Patients with advanced or metastatic head and neck cancer whose primary site of origin is the oral cavity, oropharynx, hypopharynx, larynx, nasal cavity, or paranasal sinuses.
• Patients with pathologically diagnosed squamous cell carcinoma.
• Patients who agree to undergo tumor biopsy after administration.